CD274 and triple-negative breast carcinoma: Schmid et al. 7 observed that PD-L1 expression on tumor-infiltrating immune cells as a percentage of tumor area is predictive in advanced triple-negative breast cancer patients treated with atezolizumab and nab-paclitaxel.